These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19307940)

  • 1. The utility of nucleos(t)ide-only regimens in the treatment of Mycobacterium tuberculosis-HIV-1 coinfection.
    Armstrong-James D; Menon-Johansson A; Pozniak A
    AIDS; 2009 Apr; 23(7):865-7. PubMed ID: 19307940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.
    Ena J; Leach A; Nguyen P
    HIV Med; 2008 Oct; 9(9):747-56. PubMed ID: 18651856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
    Müller AD; Myer L; Jaspan H
    Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are nonnucleoside analogue-based regimens better than protease inhibitor-based regimens for nonadherent HIV-infected patients?
    Knobel H
    Clin Infect Dis; 2005 Jan; 40(1):164-6. PubMed ID: 15614707
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiretroviral rounds. Resistance: what you don't know--can it hurt you?
    Gathe JC; Elion R
    AIDS Clin Care; 2008 Jun; 20(6):51-2. PubMed ID: 18661634
    [No Abstract]   [Full Text] [Related]  

  • 8. Understanding transmitted HIV resistance through the experience in the USA.
    Taiwo B
    Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase.
    Ray AS
    AIDS Rev; 2005; 7(2):113-25. PubMed ID: 16092505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
    Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
    AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER; Joseph K
    Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Explicitly accounting for antiretroviral drug uptake in theoretical HIV models predicts long-term failure of protease-only therapy.
    Smith RJ
    J Theor Biol; 2008 Mar; 251(2):227-37. PubMed ID: 18191950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance: what are the implications for treatment?
    Alcorn K
    IAPAC Mon; 2004 Mar; 10(3):76. PubMed ID: 15108677
    [No Abstract]   [Full Text] [Related]  

  • 15. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.
    Borget MY; Diallo K; Adje-Toure C; Chorba T; Nkengasong JN
    J Clin Virol; 2009 May; 45(1):72-5. PubMed ID: 19375979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects.
    Smith RJ; Wahl LM
    Bull Math Biol; 2004 Sep; 66(5):1259-83. PubMed ID: 15294425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis.
    Burman WJ; Gallicano K; Peloquin C
    Clin Infect Dis; 1999 Mar; 28(3):419-29; quiz 430. PubMed ID: 10194057
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment: a plethora or options in multidrug-resistant HIV-1 infection.
    Katzenstein DA
    AIDS Read; 2008 Sep; 18(9):478-9. PubMed ID: 18828232
    [No Abstract]   [Full Text] [Related]  

  • 20. Top stories of 2004. Resistance rates: high in new infections, higher in treated ones.
    Zuger A
    AIDS Clin Care; 2005 Jan; 17(1):3. PubMed ID: 15717363
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.